IRI strategic options
This article was originally published in The Tan Sheet
Executive Summary
Chicago-based market researcher has retained William Blair & Co. investment banking firm "to assist the company in its exploration of strategic options," IRI says. Firm's strategic alternatives could include "sale of all or parts of the company, joint ventures, restructuring and capital infusions in order to enhance stockholder value and to better serve our customers," Feb. 26 release states. IRI has been reeling since P&G announced plans to sever its relationship with the share-data provider in July. Chap-Cap Partners investment group, a 5.5% IRI shareholder, sent recent letter demanding IRI Chairman, President and CEO Joseph Durrett step down or sell the firm (1"The Tan Sheet" Feb. 17, 2002 , In Brief)...
You may also be interested in...
IRI on sales block?
Information Resources, Inc. shareholder Chap-Cap Partners pressures Chairman, CEO & President Joseph Durrett in Feb. 13 letter to "sell the company to the highest bidder" before "IRI's shareholders take it upon themselves to find another CEO and board of directors who will do so in your stead." El Segundo, Calif.-based investment group has collected a 5.6% stake in the market research firm since Jan. 8, shortly after Procter & Gamble announced plans to terminate its contract with IRI (1"The Tan Sheet" Dec. 16, 2002, In Brief). IRI reported flat worldwide revenues of $554.8 mil. in 2002 and a $13 mil. net loss, which followed a $3.9 mil. deficit the prior year...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.